What is Rockwell Med Inc's earnings per share (EPS)?

Rockwell Med Inc (RMTI) reported diluted earnings per share of $-0.15 for fiscal year 2025. This represents a -400.0% change compared to the previous fiscal year. EPS represents the portion of a company's net income allocated to each outstanding share of common stock and is widely used to evaluate profitability on a per-share basis.

Rockwell Med Inc Financials

RMTI

Source SEC Filings (10-K/10-Q) Updated Mar 26, 2026 Currency USD FYE March

This page shows Rockwell Med Inc (RMTI) financial statements, including the income statement, balance sheet, cash flow statement, and key financial ratios. View 17 years of annual fundamentals and quarterly data, with year-over-year growth rates and compound annual growth rates (CAGR). All figures are derived from SEC filings (10-K and 10-Q reports).

Financial Health Signals

Financial Profile 34/100

Based on FY2025 annual data. Scores normalized against common benchmarks. How we calculate these scores

Profitability

Rockwell Med Inc has an operating margin of -6.8%, meaning the company retains $-7 of operating profit per $100 of revenue. This below-average margin results in a low score of 7/100, suggesting thin profitability after operating expenses. This is down from 0.6% the prior year.

Growth

Rockwell Med Inc's revenue declined 31.8% year-over-year, from $101.5M to $69.3M. This contraction results in a growth score of 0/100.

Leverage

Rockwell Med Inc carries a low D/E ratio of 0.24, meaning only $0.24 of long-term debt for every $1 of shareholders' equity. This conservative leverage earns a score of 97/100, indicating a strong balance sheet with room for future borrowing.

Liquidity

With a current ratio of 3.98, Rockwell Med Inc holds $3.98 in current assets for every $1 of short-term obligations. This comfortable liquidity earns a score of 78/100.

Cash Flow

While Rockwell Med Inc generated -$659K in operating cash flow, capex of $542K consumed most of it, leaving -$1.2M in free cash flow. This results in a low score of 21/100, reflecting heavy capital investment rather than weak cash generation.

Returns

Rockwell Med Inc generates a -14.4% ROE, indicating limited profit relative to shareholders' investment. This results in a returns score of 0/100. This is down from -1.5% the prior year.

Piotroski F-Score Weak

2/9

Rockwell Med Inc passes 2 of 9 financial strength tests. 1 of 4 profitability signals pass, 1 of 3 leverage/liquidity signals pass, neither operating efficiency signal passes.

Earnings Quality Low Quality

0.12x

For every $1 of reported earnings, Rockwell Med Inc generates $0.12 in operating cash flow (-$659K OCF vs -$5.3M net income). This low ratio suggests earnings are primarily driven by accounting accruals rather than cash generation, which may not be sustainable.

Interest Coverage At Risk

-4.2x

Rockwell Med Inc earns $-4.2 in operating income for every $1 of interest expense (-$4.7M vs $1.1M). This narrow margin raises concern about the company's ability to service its debt if operating income declines.

Key Financial Metrics

Export CSV

Earnings & Revenue

Revenue

$69.3M

YoY-31.8%

5Y CAGR+2.2%

10Y CAGR+2.3%

Rockwell Med Inc generated $69.3M in revenue in fiscal year 2025. This represents a decrease of 31.8% from the prior year.

EBITDA

-$2.5M

YoY-189.6%

Rockwell Med Inc's EBITDA was -$2.5M in fiscal year 2025, measuring earnings before interest, taxes, depreciation, and amortization. This represents a decrease of 189.6% from the prior year.

Net Income

-$5.3M

YoY-1007.1%

Rockwell Med Inc reported -$5.3M in net income in fiscal year 2025. This represents a decrease of 1007.1% from the prior year.

EPS (Diluted)

$-0.15

YoY-400.0%

Rockwell Med Inc earned $-0.15 per diluted share (EPS) in fiscal year 2025. This represents a decrease of 400.0% from the prior year.

Cash & Balance Sheet

Free Cash Flow

-$1.2M

YoY-137.6%

Rockwell Med Inc generated -$1.2M in free cash flow in fiscal year 2025, representing cash available after capex. This represents a decrease of 137.6% from the prior year.

Cash & Debt

$10.7M

YoY-31.6%

5Y CAGR-26.1%

10Y CAGR-10.1%

Rockwell Med Inc held $10.7M in cash against $8.8M in long-term debt as of fiscal year 2025.

Dividends Per Share

N/A

Shares Outstanding

39M

YoY+15.7%

Rockwell Med Inc had 39M shares outstanding in fiscal year 2025. This represents an increase of 15.7% from the prior year.

Margins & Returns

Gross Margin

16.9%

YoY-0.3pp

5Y CAGR+12.5pp

10Y CAGR+0.7pp

Rockwell Med Inc's gross margin was 16.9% in fiscal year 2025, indicating the percentage of revenue retained after direct costs. This is down 0.3 percentage points from the prior year.

Operating Margin

-6.8%

YoY-7.4pp

5Y CAGR+38.9pp

10Y CAGR+20.5pp

Rockwell Med Inc's operating margin was -6.8% in fiscal year 2025, reflecting core business profitability. This is down 7.4 percentage points from the prior year.

Net Margin

-7.7%

YoY-7.2pp

5Y CAGR+42.0pp

10Y CAGR+18.4pp

Rockwell Med Inc's net profit margin was -7.7% in fiscal year 2025, showing the share of revenue converted to profit. This is down 7.2 percentage points from the prior year.

Return on Equity

-14.4%

YoY-12.9pp

5Y CAGR+76.0pp

10Y CAGR+8.8pp

Rockwell Med Inc's ROE was -14.4% in fiscal year 2025, measuring profit generated per dollar of shareholder equity. This is down 12.9 percentage points from the prior year.

Capital Allocation

R&D Spending

$19K

YoY+0.0%

5Y CAGR-69.4%

10Y CAGR-42.7%

Rockwell Med Inc invested $19K in research and development in fiscal year 2025. This represents an increase of 0.0% from the prior year.

Share Buybacks

N/A

Capital Expenditures

$542K

YoY-46.4%

Rockwell Med Inc invested $542K in capex in fiscal year 2025, funding long-term assets and infrastructure. This represents a decrease of 46.4% from the prior year.

RMTI Income Statement

Metric	FY25	FY24	FY23	FY22	FY21	FY20
Revenue	$69.3M-31.8%	$101.5M+21.4%	$83.6M+14.8%	$72.8M+17.6%	$61.9M-0.4%	$62.2M
Cost of Revenue	$57.6M-31.5%	$84.0M+12.1%	$74.9M+9.0%	$68.7M+6.8%	$64.4M+8.2%	$59.5M
Gross Profit	$11.7M-33.1%	$17.5M+100.9%	$8.7M+113.5%	$4.1M+268.5%	-$2.4M-188.8%	$2.7M
R&D Expenses	$19K0.0%	$19K-98.3%	$1.1M-64.5%	$3.1M-54.4%	$6.8M-3.6%	$7.1M
SG&A Expenses	$14.0M-0.5%	$14.1M+16.2%	$12.1M-22.4%	$15.6M+1.9%	$15.3M-5.2%	$16.2M
Operating Income	-$4.7M-871.5%	$608K+109.1%	-$6.7M+60.3%	-$16.8M+44.7%	-$30.3M-6.7%	-$28.4M
Interest Expense	$1.1M-10.4%	$1.3M-45.5%	$2.3M+18.9%	$1.9M-18.0%	$2.4M+25.6%	$1.9M
Income Tax	N/A	$0	$0	$0	$0	$0
Net Income	-$5.3M-1007.1%	-$480K+94.3%	-$8.4M+54.8%	-$18.7M+42.8%	-$32.7M-5.8%	-$30.9M
EPS (Diluted)	$-0.15-400.0%	$-0.03+91.9%	$-0.37+71.8%	$-1.31+65.8%	$-3.83	$-0.41

Metric	Q2'26	Q1'26	Q4'25	Q3'25	Q2'25	Q1'25	Q4'24	Q3'24
Revenue	$15.9M-0.9%	$16.1M-15.0%	$18.9M-23.3%	$24.7M-12.9%	$28.3M+9.6%	$25.8M+13.9%	$22.7M+2.6%	$22.1M
Cost of Revenue	$13.7M+0.6%	$13.6M-14.5%	$15.9M-24.5%	$21.0M-4.7%	$22.1M+3.7%	$21.3M+8.5%	$19.6M+2.0%	$19.2M
Gross Profit	$2.3M-9.2%	$2.5M-17.7%	$3.0M-16.2%	$3.6M-41.8%	$6.2M+37.1%	$4.5M+48.5%	$3.1M+6.8%	$2.9M
R&D Expenses	$0	$0	$0-100.0%	$1K	$0	$0-100.0%	$18K-89.3%	$168K
SG&A Expenses	$3.3M+1.4%	$3.3M-11.1%	$3.7M+11.6%	$3.3M-7.6%	$3.6M+3.7%	$3.4M-8.7%	$3.8M+39.4%	$2.7M
Operating Income	-$1.6M-17.4%	-$1.3M+0.8%	-$1.4M-162.0%	-$519K-126.8%	$1.9M+275.9%	$515K+138.9%	-$1.3M-142.0%	-$547K
Interest Expense	$285K+3.3%	$276K-0.4%	$277K-4.2%	$289K-4.3%	$302K+30.2%	$232K-46.2%	$431K-61.1%	$1.1M
Income Tax	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Net Income	-$1.8M-17.5%	-$1.5M+1.5%	-$1.5M-100.4%	-$756K-145.4%	$1.7M+385.1%	$343K+119.8%	-$1.7M-14.5%	-$1.5M
EPS (Diluted)	$-0.050.0%	$-0.05-25.0%	$-0.04	N/A	$0.04+300.0%	$0.01+116.7%	$-0.06	N/A

RMTI Balance Sheet

Metric	FY25	FY24	FY23	FY22	FY21	FY20
Total Assets	$57.1M-3.5%	$59.2M+13.5%	$52.2M+11.9%	$46.6M-4.0%	$48.6M-37.5%	$77.7M
Current Assets	$38.2M+3.1%	$37.0M+28.7%	$28.8M-18.5%	$35.3M+0.1%	$35.3M-49.2%	$69.5M
Cash & Equivalents	$10.7M-31.6%	$15.7M+74.4%	$9.0M-11.1%	$10.1M-23.9%	$13.3M-72.7%	$48.7M
Inventory	$3.4M-40.7%	$5.8M-1.6%	$5.9M+1.0%	$5.8M+42.6%	$4.1M+4.2%	$3.9M
Accounts Receivable	$8.1M-1.8%	$8.3M-23.9%	$10.9M+74.2%	$6.3M+5.9%	$5.9M+41.8%	$4.2M
Goodwill	$921K0.0%	$921K0.0%	$921K0.0%	$921K0.0%	$921K0.0%	$921K
Total Liabilities	$20.2M-24.3%	$26.6M-13.8%	$30.9M-5.1%	$32.5M-29.3%	$46.0M+5.6%	$43.6M
Current Liabilities	$9.6M-32.0%	$14.1M-15.3%	$16.6M-6.0%	$17.7M-15.6%	$21.0M+63.9%	$12.8M
Long-Term Debt	$8.8M+4.2%	$8.5M+2.2%	$8.3M+9.8%	$7.6M-42.7%	$13.2M-37.1%	$20.9M
Total Equity	$37.0M+13.5%	$32.6M+53.1%	$21.3M+50.9%	$14.1M+456.4%	$2.5M-92.6%	$34.2M
Retained Earnings	-$403.0M-1.3%	-$397.7M-0.1%	-$397.2M-2.2%	-$388.8M-5.0%	-$370.1M-9.7%	-$337.4M

Metric	Q2'26	Q1'26	Q4'25	Q3'25	Q2'25	Q1'25	Q4'24	Q3'24
Total Assets	$57.5M+9.2%	$52.6M-2.5%	$54.0M-8.9%	$59.2M+3.7%	$57.1M+7.6%	$53.0M+4.5%	$50.7M-2.8%	$52.2M
Current Assets	$37.5M+18.7%	$31.6M-4.3%	$33.0M-10.8%	$37.0M+8.2%	$34.2M+15.0%	$29.8M+11.5%	$26.7M-7.2%	$28.8M
Cash & Equivalents	$13.6M+9.0%	$12.5M+9.6%	$11.4M-27.3%	$15.7M+26.9%	$12.3M+4.0%	$11.9M+78.6%	$6.6M-26.1%	$9.0M
Inventory	$4.0M-4.7%	$4.2M-17.5%	$5.0M-12.7%	$5.8M-1.9%	$5.9M+0.1%	$5.9M-3.1%	$6.1M+3.4%	$5.9M
Accounts Receivable	$8.3M+3.0%	$8.1M-16.4%	$9.7M+16.6%	$8.3M-6.7%	$8.9M-18.0%	$10.8M-2.3%	$11.1M+1.8%	$10.9M
Goodwill	$921K0.0%	$921K0.0%	$921K0.0%	$921K0.0%	$921K0.0%	$921K0.0%	$921K0.0%	$921K
Total Liabilities	$20.5M-7.9%	$22.2M-1.0%	$22.4M-15.7%	$26.6M-4.7%	$27.9M-5.4%	$29.5M-1.8%	$30.1M-2.6%	$30.9M
Current Liabilities	$9.6M-12.5%	$10.9M-2.3%	$11.2M-20.5%	$14.1M-0.6%	$14.2M-4.8%	$14.9M-0.4%	$14.9M-10.1%	$16.6M
Long-Term Debt	$8.7M+1.0%	$8.6M+1.0%	$8.6M+1.0%	$8.5M+1.1%	$8.4M+1.1%	$8.3M+0.4%	$8.3M-0.3%	$8.3M
Total Equity	$37.0M+21.7%	$30.4M-3.5%	$31.5M-3.3%	$32.6M+11.8%	$29.1M+24.0%	$23.5M+13.8%	$20.6M-3.0%	$21.3M
Retained Earnings	-$402.4M-0.4%	-$400.7M-0.4%	-$399.2M-0.4%	-$397.7M-0.2%	-$396.9M+0.4%	-$398.6M+0.1%	-$398.9M-0.4%	-$397.2M

RMTI Cash Flow Statement

Metric	FY25	FY24	FY23	FY22	FY21	FY20
Operating Cash Flow	-$659K-115.7%	$4.2M+144.6%	-$9.4M+44.4%	-$16.9M+49.5%	-$33.5M-13.1%	-$29.6M
Capital Expenditures	$542K-46.4%	$1.0M+256.0%	$284K	N/A	N/A	N/A
Free Cash Flow	-$1.2M-137.6%	$3.2M+132.9%	-$9.7M	N/A	N/A	N/A
Investing Cash Flow	-$8.5M-75.6%	-$4.9M-59.8%	-$3.0M-27.1%	-$2.4M-870.4%	$311K-90.3%	$3.2M
Financing Cash Flow	$4.3M-42.1%	$7.3M-35.2%	$11.3M-29.8%	$16.1M+841.2%	-$2.2M-103.4%	$63.3M
Dividends Paid	N/A	N/A	N/A	N/A	N/A	N/A
Share Buybacks	N/A	N/A	N/A	N/A	N/A	N/A

Metric	Q2'26	Q1'26	Q4'25	Q3'25	Q2'25	Q1'25	Q4'24	Q3'24
Operating Cash Flow	-$1.3M-170.9%	$1.8M+152.9%	-$3.5M-503.1%	$865K-79.8%	$4.3M+196.5%	$1.4M+160.6%	-$2.4M-5434.9%	-$43K
Capital Expenditures	$229K+39.6%	$164K+160.3%	$63K-84.1%	$395K+106.8%	$191K-33.2%	$286K+105.8%	$139K+223.3%	$43K
Free Cash Flow	-$1.5M-191.4%	$1.7M+147.3%	-$3.5M-855.3%	$470K-88.5%	$4.1M+253.3%	$1.2M+145.9%	-$2.5M-2829.1%	-$86K
Investing Cash Flow	-$4.3M-4083.5%	-$103K-10200.0%	-$1K+99.7%	-$332K+94.6%	-$6.1M-456.0%	$1.7M+1335.3%	-$139K-106.9%	$2.0M
Financing Cash Flow	$6.7M+1137.5%	-$650K+17.0%	-$783K-128.0%	$2.8M+20.7%	$2.3M+12.0%	$2.1M+1060.1%	$178K+124.0%	-$742K
Dividends Paid	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Share Buybacks	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A

RMTI Financial Ratios

Metric	FY25	FY24	FY23	FY22	FY21	FY20
Gross Margin	16.9%-0.3pp	17.2%+6.8pp	10.4%+4.8pp	5.6%+9.5pp	-3.9%-8.3pp	4.4%
Operating Margin	-6.8%-7.4pp	0.6%+8.6pp	-8.0%+15.1pp	-23.1%+25.9pp	-49.0%-3.3pp	-45.7%
Net Margin	-7.7%-7.2pp	-0.5%+9.6pp	-10.1%+15.6pp	-25.7%+27.1pp	-52.8%-3.1pp	-49.7%
Return on Equity	-14.4%-12.9pp	-1.5%+38.2pp	-39.6%+92.8pp	-132.4%+1156.5pp	-1288.9%-1198.5pp	-90.4%
Return on Assets	-9.3%-8.5pp	-0.8%+15.4pp	-16.2%+23.9pp	-40.1%+27.2pp	-67.3%-27.5pp	-39.7%
Current Ratio	3.98+1.4	2.63+0.9	1.73-0.3	2.00+0.3	1.68-3.7	5.43
Debt-to-Equity	0.24-0.0	0.26-0.1	0.39-0.1	0.54-4.7	5.20+4.6	0.61
FCF Margin	-1.7%-4.9pp	3.1%+14.7pp	-11.6%	N/A	N/A	N/A

Metric	Q2'26	Q1'26	Q4'25	Q3'25	Q2'25	Q1'25	Q4'24	Q3'24
Gross Margin	14.3%-1.3pp	15.6%-0.5pp	16.1%+1.4pp	14.7%-7.3pp	22.0%+4.4pp	17.6%+4.1pp	13.5%+0.5pp	13.0%
Operating Margin	-10.0%-1.6pp	-8.4%-1.2pp	-7.2%-5.1pp	-2.1%-8.9pp	6.8%+4.9pp	2.0%+7.8pp	-5.8%-3.4pp	-2.5%
Net Margin	-11.0%-1.7pp	-9.3%-1.3pp	-8.0%-4.9pp	-3.1%-8.9pp	5.9%+4.5pp	1.3%+9.0pp	-7.6%-0.8pp	-6.8%
Return on Equity	-4.7%+0.2pp	-4.9%-0.1pp	-4.8%-2.5pp	-2.3%-8.0pp	5.7%+4.3pp	1.5%+9.8pp	-8.4%-1.3pp	-7.1%
Return on Assets	-3.0%-0.2pp	-2.8%-0.0pp	-2.8%-1.5pp	-1.3%-4.2pp	2.9%+2.3pp	0.7%+4.1pp	-3.4%-0.5pp	-2.9%
Current Ratio	3.92+1.0	2.89-0.1	2.95+0.3	2.63+0.2	2.41+0.4	2.00+0.2	1.79+0.1	1.73
Debt-to-Equity	0.24-0.0	0.28+0.0	0.27+0.0	0.26-0.0	0.29-0.1	0.35-0.0	0.40+0.0	0.39
FCF Margin	-9.6%-20.1pp	10.4%+29.2pp	-18.8%-20.7pp	1.9%-12.5pp	14.4%+9.9pp	4.5%+15.6pp	-11.1%-10.7pp	-0.4%

Similar Companies

DURECT DRRX

$59.3M

Assertio Holdings Inc ASRT

$124.1M

Cumberland Pharmaceuticals Inc CPIX

$46.4M

Intercure Ltd. INCR

$41.0M

Cardiol Therapeu CRDL

$155.2M

Frequently Asked Questions

What is Rockwell Med Inc's annual revenue?

Rockwell Med Inc (RMTI) reported $69.3M in total revenue for fiscal year 2025. This represents a -31.8% change compared to the previous fiscal year. Revenue measures the total income earned from the company's primary business operations before any expenses are deducted.

How fast is Rockwell Med Inc's revenue growing?

Rockwell Med Inc (RMTI) revenue declined by 31.8% year-over-year, from $101.5M to $69.3M in fiscal year 2025.

Is Rockwell Med Inc profitable?

No, Rockwell Med Inc (RMTI) reported a net income of -$5.3M in fiscal year 2025, with a net profit margin of -7.7%.

What is Rockwell Med Inc's EBITDA?

Rockwell Med Inc (RMTI) had EBITDA of -$2.5M in fiscal year 2025, measuring earnings before interest, taxes, depreciation, and amortization.

How much debt does Rockwell Med Inc have?

As of fiscal year 2025, Rockwell Med Inc (RMTI) had $10.7M in cash and equivalents against $8.8M in long-term debt.

What is Rockwell Med Inc's gross margin?

Rockwell Med Inc (RMTI) had a gross margin of 16.9% in fiscal year 2025, indicating the percentage of revenue retained after direct costs of goods sold.

What is Rockwell Med Inc's operating margin?

Rockwell Med Inc (RMTI) had an operating margin of -6.8% in fiscal year 2025, reflecting the profitability of core business operations before interest and taxes.

What is Rockwell Med Inc's net profit margin?

Rockwell Med Inc (RMTI) had a net profit margin of -7.7% in fiscal year 2025, representing the share of revenue converted into profit after all expenses.

What is Rockwell Med Inc's return on equity (ROE)?

Rockwell Med Inc (RMTI) has a return on equity of -14.4% for fiscal year 2025, measuring how efficiently the company generates profit from shareholder equity.

What is Rockwell Med Inc's free cash flow?

Rockwell Med Inc (RMTI) generated -$1.2M in free cash flow during fiscal year 2025. This represents a -137.6% change compared to the previous fiscal year. Free cash flow represents the cash a company generates after accounting for capital expenditures, and is widely used to assess financial flexibility and shareholder value.

What is Rockwell Med Inc's operating cash flow?

Rockwell Med Inc (RMTI) generated -$659K in operating cash flow during fiscal year 2025, representing cash generated from core business activities.

What are Rockwell Med Inc's total assets?

Rockwell Med Inc (RMTI) had $57.1M in total assets as of fiscal year 2025, including both current and long-term assets.

What are Rockwell Med Inc's capital expenditures?

Rockwell Med Inc (RMTI) invested $542K in capital expenditures during fiscal year 2025, funding long-term assets and infrastructure.

How much does Rockwell Med Inc spend on research and development?

Rockwell Med Inc (RMTI) invested $19K in research and development during fiscal year 2025.

How many shares does Rockwell Med Inc have outstanding?

Rockwell Med Inc (RMTI) had 39M shares outstanding as of fiscal year 2025.

What is Rockwell Med Inc's current ratio?

Rockwell Med Inc (RMTI) had a current ratio of 3.98 as of fiscal year 2025, which is generally considered healthy.

What is Rockwell Med Inc's debt-to-equity ratio?

Rockwell Med Inc (RMTI) had a debt-to-equity ratio of 0.24 as of fiscal year 2025, measuring the company's financial leverage by comparing total debt to shareholder equity.

What is Rockwell Med Inc's return on assets (ROA)?

Rockwell Med Inc (RMTI) had a return on assets of -9.3% for fiscal year 2025, measuring how efficiently the company uses its assets to generate profit.

What is Rockwell Med Inc's cash runway?

Based on fiscal year 2025 data, Rockwell Med Inc (RMTI) had $10.7M in cash against an annual operating cash burn of $659K. This gives an estimated cash runway of approximately 195 months at the current burn rate. Cash runway measures how long a company can continue operating before running out of cash, assuming no additional funding.

What is Rockwell Med Inc's Piotroski F-Score?

Rockwell Med Inc (RMTI) has a Piotroski F-Score of 2 out of 9, indicating weak financial health. The F-Score evaluates nine binary signals across profitability (positive ROA, positive cash flow, improving ROA, earnings quality), leverage (decreasing debt, improving liquidity, no share dilution), and operating efficiency (improving gross margin, improving asset turnover). Scores of 7–9 indicate strong and improving fundamentals. Learn more in our complete guide to financial health indicators.

Are Rockwell Med Inc's earnings high quality?

Rockwell Med Inc (RMTI) has an earnings quality ratio of 0.12x, considered low quality (accrual-driven). This ratio compares operating cash flow to net income. A ratio above 1.0x means the company generates more cash than its reported earnings, indicating sustainable, cash-backed profits. Ratios below 1.0x suggest earnings rely on accounting accruals rather than actual cash generation. Learn more in our complete guide to financial health indicators.

Can Rockwell Med Inc cover its interest payments?

Rockwell Med Inc (RMTI) has an interest coverage ratio of -4.2x, meaning it can struggle to cover its interest obligations. This ratio divides operating income by interest expense. Ratios above 5x indicate strong debt-servicing ability, while ratios below 2x suggest the company may face difficulty meeting interest payments if earnings decline. Learn more in our complete guide to financial health indicators.

How financially healthy is Rockwell Med Inc?

Rockwell Med Inc (RMTI) scores 34 out of 100 on our Financial Profile, indicating weak overall financial health. This composite score evaluates six dimensions: profitability (operating margin), revenue growth, leverage (debt-to-equity), liquidity (current ratio), cash flow quality (free cash flow margin), and shareholder returns (return on equity). Each dimension is normalized against standard financial benchmarks. Learn more in our complete guide to financial health indicators.